跳转至内容
Merck
HomeCancer ResearchAuthenticated Colorectal Cancer Cell Lines for Cancer Research

Authenticated Colorectal Cancer Cell Lines for Cancer Research

Colorectal cancer (CRC) is the second most common cancer in women, and the third most common in men. For statistics combining men and women, CRC is the fourth leading cause of cancer mortality. More than half of the CRC cases reported are in developed countries, with the incidence increasing in developing countries. Colorectal cancer accounts for 10% of cancer-related deaths in western countries. Despite innovative therapeutic advances, mortality rates for colorectal cancer patients remains high1.

Types of cancer

Most colorectal cancers are classified as adenocarcinomas. Other, less common, types include gastrointestinal stromal tumor (GIST), carcinoid or neuroendocrine tumors, small cell carcinomas, and lymphomas, which typically start in cells of the immune system, but can also arise in other organs such as the colon or rectum1.

Cancer cell panels listed below are derived from adenocarcinoma.

Risk factors

Etiology and risk factors are both genetic and environmental. There is an increase in the incidence of colorectal cancer if first-degree family members are positive for the disease1.  Lifestyle factors like smoking, alcohol consumption and obesity also increase the incidence of colorectal cancer.

Mutations

The most common genes altered (mutations with frequency >30%) in colorectal cancer includes APC, TP53, ERBB2, KRASPTEN, and BRAF.

Choose cell lines from the table below based on mutation, and click genes to find relevant products (antibodies, shRNA, siRNA, primers, CRISPR plasmids) for your research study.

Table1. Colorectal cancer cell lines with specific somatic mutations

Small molecules/monoclonal antibodies

Small molecule compounds and antibodies can be used to target specific cancer cells and block tumor growth and progression. The most common drugs used to target colorectal cancer include:

Applications

Cancer cell lines are the foundation for cancer research, and provide an accessible, cost-effective model for cellular behavior and response. Based on the characteristics of the cell line and experimental need, cell lines may be used in one or more applications. Some examples of application-specific cell line use are included below.

References

1.
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJH, Watanabe T. 2015. Colorectal cancer. Nat Rev Dis Primers. 1(1): https://doi.org/10.1038/nrdp.2015.65
2.
Hoffmann OI, Ilmberger C, Magosch S, Joka M, Jauch K, Mayer B. 2015. Impact of the spheroid model complexity on drug response. Journal of Biotechnology. 20514-23. https://doi.org/10.1016/j.jbiotec.2015.02.029
3.
Kim KS, Lee YK, Kim JS, Koo KH, Hong HJ, Park YS. 2008. Targeted gene therapy of LS174?T human colon carcinoma by anti-TAG-72 immunoliposomes. Cancer Gene Ther. 15(5):331-340. https://doi.org/10.1038/cgt.2008.11
4.
Rowehl RA, Burke S, Bialkowska AB, Pettet DW, Rowehl L, Li E, Antoniou E, Zhang Y, Bergamaschi R, Shroyer KR, et al. Establishment of Highly Tumorigenic Human Colorectal Cancer Cell Line (CR4) with Properties of Putative Cancer Stem Cells. PLoS ONE. 9(6):e99091. https://doi.org/10.1371/journal.pone.0099091
5.
LI K, ZHOU Z, JI P, LUO H. 2016. Knockdown of ?-catenin by siRNA influences proliferation, apoptosis and invasion of the colon cancer cell line SW480. 11(6):3896-3900. https://doi.org/10.3892/ol.2016.4481
6.
Ai S, Jia T, Ai W, Duan J, Liu Y, Chen J, Liu X, Yang F, Tian Y, Huang Z. 2013. Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells. Br J Pharmacol. 168(7):1719-1735. https://doi.org/10.1111/bph.12055
7.
Giromini C, Baldi A, Fusi E, Rebucci R, Purup S. 2015. Effect of growth factors, estradiol 17-?, and short chain fatty acids on the intestinal HT29-MTX cells. Cell Biol Toxicol. 31(4-5):199-209. https://doi.org/10.1007/s10565-015-9304-y
8.
ZHANG Y, LIN L, JIN Y, LIN Y, CAO Y, ZHENG C. 2016. Overexpression of WNT5B promotes COLO 205 cell migration and invasion through the JNK signaling pathway. 36(1):23-30. https://doi.org/10.3892/or.2016.4772
9.
Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S. 2008. Effect of Adiponectin and Ghrelin on Apoptosis of Barrett Adenocarcinoma Cell Line. Dig Dis Sci. 53(3):597-605. https://doi.org/10.1007/s10620-007-9922-1
10.
Petrova YI, Schecterson L, Gumbiner BM. 2016. Roles for E-cadherin cell surface regulation in cancer. MBoC. 27(21):3233-3244. https://doi.org/10.1091/mbc.e16-01-0058
登录以继续。

如要继续阅读,请登录或创建帐户。

暂无帐户?